Georgia Cancer Center, Augusta University, Augusta, Georgia, USA.
Department of Haematology, University Hospitals Bristol, NHS Foundation Trust, Bristol, UK.
Am J Hematol. 2021 Apr 1;96(4):493-507. doi: 10.1002/ajh.26079. Epub 2021 Jan 12.
Treatment of older patients with AML remains challenging. Although age, performance status, and comorbidities are commonly employed to determine fitness for intensive treatment, several studies have demonstrated improved outcomes with treatment in older and classically unfit patients, highlighting the importance of other disease-related and patient-related factors that have prognostic value for treatment outcome in AML. However, consistent and objective assessments for fitness are lacking. Multi-parameter geriatric assessment tools offer more comprehensive evaluation, but are limited by the required resources and lack of standardization and consensus regarding prognostic value. These assessments are particularly important considering the emerging new AML therapies that represent a spectrum of intensities. Patients should therefore be evaluated holistically for fitness to receive a specific treatment, with the aim of providing individualized care, and such definitions of fitness should also consistently be applied to clinical trials. This review will examine evolving criteria for the determination of fitness among AML patients and discuss treatment options for older and/or unfit patients with AML.
治疗老年 AML 患者仍然具有挑战性。尽管年龄、体能状态和合并症通常用于确定是否适合强化治疗,但多项研究表明,在老年和经典不适合治疗的患者中进行治疗可改善结局,这突出了其他与疾病相关和与患者相关的因素对 AML 治疗结果具有预后价值。然而,目前缺乏一致和客观的体能评估方法。多参数老年评估工具提供了更全面的评估,但受到所需资源的限制,并且在预后价值方面缺乏标准化和共识。考虑到新兴的新型 AML 疗法代表了一系列的强度,这些评估尤其重要。因此,患者应全面评估接受特定治疗的体能,以提供个体化的护理,并且这些体能定义也应一致应用于临床试验。本综述将探讨 AML 患者体能评估的不断发展的标准,并讨论 AML 老年和/或不适合治疗患者的治疗选择。